濮阳市东方医院具体位置在哪濮阳东方男科看病好,濮阳东方医院男科割包皮手术好不好,濮阳东方医院看妇科收费非常低,濮阳东方看妇科病收费正规,濮阳东方妇科医院看病便宜吗,濮阳东方医院男科治阳痿评价很好,濮阳东方妇科医院做人流手术费用多少

SHENZHEN, June 18 (Xinhua) -- China established its first national gene bank on Friday in south China's city of Shenzhen with the support of the Beijing Genomics Institute (BGI), officials said.With the establishment of the National Gene Bank in Shenzhen, China will be able to better protect, research and utilize its precious genetic resources, boosting the genetics industry and safeguarding the country's genetic information, said Qi Chengyuan, head of the high-tech industry department of the National Development and Reform Committee (NDRC).The gene bank, which was approved by the NDRC in January, is based on data and facilities belonging to the BGI, but will grow with the help of extensive cooperation with other biological organizations both home and abroad, Qi said.The national gene bank "aims to lead the development of international bioindustry as one of the world's largest gene banks," said Yang Huanming, the BGI's president.The BGI, the world's largest genome-mapping institute, has more than 1,000 biological analysis devices working with top-of-the-line genome-sequencing machines.Analysts say the BGI differs from conventional labs, as it can handle data in vast quantities and industrialize its research. Some believe lower wages in China have also contributed to the BGI's competitiveness.Yang Bicheng, the BGI's spokesman, said the payment and welfare packages BGI offers are competitive in China's bioindustry."A researcher with about two years of experience earns around 100,000 yuan (15,440 U.S. dollars) a year. More outstanding researchers can get more, but the gap is not too great," Yang said.Yang said greater motivation comes from better prospects for academic achievements."Our young researchers can work with the world's leading scientists, participate in global science projects and be pioneers in new fields of research. Only BGI offers these kinds of opportunities in China," Yang said.The BGI has published 18 research papers in Science Magazine and the Nature Journal since 2007. The facility has become an international center for genome research and industrialization, with advanced technology and top talent, said Ji Xiaoming, head of the international cooperation department of the Ministry of Science and Technology.China is working to make its genetic research industry into one of the country's pillar industries.A plan approved by the State Council, or China's cabinet, in October 2010 said China will boost the industry by encouraging innovation, promoting industrial application of biological research, fostering market demand and deepening international cooperation.

WASHINGTON, July 15 (Xinhua) -- Researchers at Mount Sinai School of Medicine have found that grape seed polyphenols -- a natural antioxidant -- may help prevent the development or delay the progression of Alzheimer's disease.The research, led by Giulio Pasinetti, was published online Friday in the Journal of Alzheimer's Disease, which causes brain changes that gradually get worse.This is the first study to evaluate the ability of grape- derived polyphenols to prevent the generation of a specific form of amyloid (A) peptide, a substance in the brain long known to cause the neurotoxicity associated with Alzheimer's disease.In partnership with a team at the University of Minnesota, Pasinetti and collaborators administered grape seed polyphenolic extracts to mice genetically determined to develop memory deficits and A neurotoxins similar to those found in Alzheimer's disease. They found that the brain content of the A*56, a specific form of A previously implicated in the promotion of Alzheimer's disease memory loss, was substantially reduced after treatment.Previous studies suggest that increased consumption of grape- derived polyphenols, whose content, for example, is very high in red wine, may protect against cognitive decline in Alzheimer's. This new finding corroborates those theories."Since naturally occurring polyphenols are also generally commercially available as nutritional supplements and have negligible adverse events even after prolonged periods of treatment, this new finding holds significant promise as a preventive method or treatment, and is being tested in translational studies in Alzheimer's disease patients," said Pasinetti.In Alzheimer's disease, brain cells degenerate and die, causing a steady decline in memory and mental function.

SAN FRANCISCO, Aug. 9 (Xinhua) -- Nokia is planning to stop selling its low-end phones and smartphones in the United States, instead focusing on products using Microsoft's Windows Phone platform, U.S. media reported on Tuesday.The Finnish handset maker will end sales of its low-end Series 40 phones and smartphones based on the Symbian mobile operating system in the United States and Canada, as it needs to put all of its efforts into the Windows Phone products which are due out later this year, Chris Weber, head of Nokia's U.S. subsidiary, told technology news site All Things Digital."When we launch Windows Phones we will essentially be out of the Symbian business, the S40 business, etc.," Weber said.Staff members speak to trade visitors at the Nokia booth at the CommunicAsia expo in Singapore June 21, 2011.In February, Nokia and Microsoft announced plans to form a broad strategic partnership, under which Nokia agrees to adopt Windows Phone as its principal smartphone strategy.North America is a priority for Nokia, Weber noted, in part because it is a key market for Microsoft and also because Nokia sees it as a key to winning in the smartphone battle globally."We'll develop for North America and make the phones globally available and applicable," Weber said.In another development, technology blog Engadget and other U.S. media on Tuesday reported that Nokia will not bring N9, its first smartphone running the Linux-based mobile operating system MeeGo, to the U.S. market."After the very positive reception to the launch of the Nokia N9, the product is now being rolled out in countries around the world. At this time we will not be making it available in the U.S., " Nokia said in a statement.

WASHINGTON, Sept. 12 (Xinhua) -- An enzyme that appears to play a role in controlling the brain's response to nicotine and alcohol in mice might be a promising target for a drug that simultaneously would treat nicotine addiction and alcohol abuse in people, U.S. researchers find.Over the course of four weeks, mice genetically engineered to lack the gene for protein kinase C (PKC) epsilon consumed less of a nicotine-containing water solution than normal mice, and were less likely to return to a chamber in which they had been given nicotine. In contrast, normal mice steadily increased their consumption of nicotine solution while the mice lacking PKC epsilon did not.The study conducted by researchers at the Ernest Gallo Clinic and Research Center, affiliated with the University of California, San Francisco, appeared Monday in the online edition of the Proceedings of the National Academy of Sciences.In normal mice, as in humans, nicotine binds to a certain class of nicotinic receptors located on dopamine neurons, which causes dopamine to be released in the brain. Dopamine creates a feeling of enjoyment, and thus prompts a sense of reward. Researchers found that mice lacking PKC epsilon are deficient in these nicotinic receptors.The finding complements earlier research in which researchers found that mice genetically engineered to lack the PKC epsilon enzyme drank less alcohol than normal mice and were disinclined to return to a chamber in which they had been given alcohol."This could mean that these mice might not get the same sense of reward from nicotine or alcohol," said Gallo senior associate director and investigator Robert Messing. "The enzyme looks like it regulates the part of the reward system that involves these nicotinic receptors."The reward system is a complex of areas in the brain that affect craving for nicotine, alcohol and other addictive substances.The next step in the research, said Messing, would be to develop compounds that inhibit PKC epsilon. The ultimate goal, he added, would be medications that could be used "to take the edge off of addiction by helping people get over some of their reward craving."

BUJUMBURA, May 31(Xinhua) -- As the World No Tobacco Day is celebrated on Tuesday, many Burundians feel happy that they have given up smoking thanks to herbal drugs.Evariste Ndikumwami, 55, residing in the Burundian capital Bujumbura, said he had been smoking for 30 years, but gave up smoking in January after taking herbal drugs prescribed by an abbot."I had been smoking since my teenage and I gave up smoking in January (this year) after I took herbal drugs that I got from a Roman Catholic priest from Uganda working at Rugari parish in the province of Muyinga, some 210 km northeast of the Burundian capital Bujumbura," Ndikumwami told Xinhua.Ndikumwami said he used to smoke a pack of 20 cigarettes per day, adding that he had found it hard to give up smoking.He said, "I took the herbal drugs for 15 days. The abbot prescribed me two herbal drugs -- one to be smoked for five days at daytime when I desire to smoke and another one to be applied around the nostrils at night."After the medication period, he never felt the desire for smoking cigarettes, he said."When my friends realized I was no longer smoking, they asked me which drugs I took to give up smoking. I directed them to the abbot who had healed me and they also got cured and stopped smoking," Ndikumwami said.